Biotech | November 18, 2021
AstraZeneca’s Covid-19 drug offers 83% protection over six months
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Early detection of breast cancer increases survival rate by 95 per cent
Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India
The octocopter has successfully delivered 50 vials of Covid-19 vaccines along with syringes in a special container from Chandapura PHC to Haragadde PHC
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week
The start-up has announced the scheme to mark World Diabetes Day
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Evidence also shows better immune response to virus among users of spray
Subscribe To Our Newsletter & Stay Updated
